A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells.
about
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow MicroenvironmentMicroRNAs in multiple myeloma and related bone diseaseIntratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategiesA novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic diseaseCharacterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessmentEx-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapyTargeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity.Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myelomaEx Vivo Maintenance of Primary Human Multiple Myeloma Cells through the Optimization of the Osteoblastic Niche.Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.Promises and challenges of MicroRNA-based treatment of multiple myelomaPreclinical animal models of multiple myelomaA 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma.Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice.A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications.Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma.Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma.Immunologic microenvironment and personalized treatment in multiple myeloma.Emerging pathways as individualized therapeutic target of multiple myeloma.Preclinical models of multiple myeloma: a critical appraisal.Immunological dysregulation in multiple myeloma microenvironment.Mir-34: a new weapon against cancer?Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities.miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.Mir-221/222 are promising targets for innovative anticancer therapy.3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma.miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease.Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myelomamiR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells
P2860
Q26765477-E497C28D-BC56-4BBC-92FD-EFE58F548E37Q26770478-677C2042-6C84-4D55-9DC5-2538F20BDB4AQ27302313-593D21E5-0315-4CEF-986B-DB4181CF18EDQ27329429-EDB7F968-CCF8-4695-BBA2-447595AA9499Q28486349-DEC53035-D6FB-46F2-B0E7-2C83F59ADE29Q28535634-73F7AC24-662D-4BFE-AD32-2725EBC2D5F5Q33917555-93A389B4-3A18-4AF2-AC50-55B542B32943Q34103347-B46F61B1-9E1A-4269-9ED8-AD5403ADABBCQ34773850-5C2A2D6B-F633-4516-B0E3-0556C8AE8AE2Q35108549-482241CA-9004-4F8B-8454-2225945C7C00Q35631433-1F6DBD9B-8CDB-4443-B662-2D7DCBF4B967Q35678607-649A0D95-23A5-4A01-AA65-7C2AF8F43187Q35766816-EE41DDD5-E264-4BA8-AB03-691AA0D511E0Q36051868-BEC20D7C-EDD8-42BF-A281-DFED661025C0Q36254566-8D391568-8377-4C69-94AB-BF7EACC0839DQ36419086-EAA5A58D-6763-45DB-9A69-29D8D8013BC8Q36561366-4637BF07-2423-4018-88F4-13DFF7CDDAC1Q36642951-99EF45A2-F51C-4D2A-997D-25CF8F760421Q37016562-7B86BA5F-BB0B-4912-8A9A-3306CCC6EE8DQ37031293-6926A8CB-B1B6-410D-BD21-9ACF46C6C6E3Q37402009-6BBC9E1C-C3B2-4612-8C51-0AE6D22C4EE7Q37709866-DAB79778-8031-4967-9461-BAAE94AF960BQ37953844-289D5707-D696-4439-82B3-6DC203EF3FD2Q38016511-7E3B3B3A-2AF6-49DF-8E71-B647DD397248Q38056889-35B7E4D2-7375-4A1F-BC25-1C0262A444CEQ38108387-A5F80785-1672-4988-BE5A-3206514449BFQ38108390-D0316F2C-8664-4F81-866D-E8D2AC94AB83Q38112176-2376B37E-7C5B-42B5-933C-CB97049B0731Q38112468-319DB72E-9C76-47E5-9882-913D3E786586Q38228353-39FACCA7-C108-4ECA-B80B-45D2CFA20AF3Q38253374-7451D029-50FF-407A-B8A1-77FAC5B318C3Q38299932-D11A1D3A-1631-4D12-A51A-5F4598C43FAEQ38476564-42312051-2E7A-4909-9892-B7F1D698CD66Q38767024-3DAE8087-238E-4376-BF8C-69EB8B86D671Q38832888-E2635723-B8D1-4E4B-BDF5-743DC4EC4788Q38854653-6547BD02-69F7-4154-9757-F6EE6DF116A4Q39139112-826B6327-CFC1-4EC2-9440-452E119728ACQ39223387-C2BEC78A-540A-4A23-8E88-5B8ADCE59709Q40856384-8D0E7372-7673-4794-A167-1D29ACC1A5A4Q41894298-5496F43A-3D8D-4919-8656-0CA1ABFD8DB2
P2860
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A unique three-dimensional SCI ...... rimary multiple myeloma cells.
@en
A unique three-dimensional SCID-polymeric scaffold
@nl
type
label
A unique three-dimensional SCI ...... rimary multiple myeloma cells.
@en
A unique three-dimensional SCID-polymeric scaffold
@nl
prefLabel
A unique three-dimensional SCI ...... rimary multiple myeloma cells.
@en
A unique three-dimensional SCID-polymeric scaffold
@nl
P2093
P2860
P50
P356
P1433
P1476
A unique three-dimensional SCI ...... primary multiple myeloma cells
@en
P2093
F Conforti
K C Anderson
M T Di Martino
P Tagliaferri
P2860
P2888
P304
P356
10.1038/LEU.2010.300
P577
2011-01-14T00:00:00Z
P5875
P6179
1015175175